HLN

Haleon PLC

Add to Watchlist

Advanced Chart

9.600

+0.01(0.104%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

9.710

Open

9.685

VWAP

9.64

Vol

9.29M

Mkt Cap

43.13B

Low

9.555

Amount

89.49M

EV/EBITDA(TTM)

Total Shares

4.57B

40.16B

EV/OCF(TTM)

P/S(TTM)

Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

2.86B

+3.57%

2.81B

+1.01%

2.70B

-2.61%

Estimates Revision

The market is revising Downward the revenue expectations for Haleon plc (HLN) for FY2025, with the revenue forecasts being adjusted by -2.51% over the past three months. During the same period, the stock price has changed by -5.79%.

Revenue Estimates for FY2025

Revise Downward

-2.51%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-3.05%

In Past 3 Month

Stock Price

Go Down

-5.79%

In Past 3 Month

3 Analyst Rating

32.60% Upside

Wall Street analysts forecast HLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HLN is 12.73 USD with a low forecast of 11.25 USD and a high forecast of 13.54 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

32.60% Upside

Current: 9.600

Low

11.25

Averages

12.73

High

13.54

32.60% Upside

Current: 9.600

Low

11.25

Averages

12.73

High

13.54

Barclays

Overweight

NULL

downgrade

$475 -> $450

2025-07-08

Reason

Barclays

Price Target

$475 -> $450

2025-07-08

downgrade

Overweight

NULL

Reason

Barclays lowered the firm's price target on Haleon to 450 GBp from 475 GBp and keeps an Overweight rating on the shares.

Morgan Stanley

Overweight

downgrade

2025-07-08

Reason

Morgan Stanley

Price Target

2025-07-08

downgrade

Overweight

Reason

Morgan Stanley lowered the firm's price target on Haleon to 410 GBp from 425 GBp and keeps an Overweight rating on the shares.

Berenberg

Bethan Davies

Buy

maintain

2025-06-21

Reason

Berenberg

Bethan Davies

Price Target

2025-06-21

maintain

Buy

Reason

Berenberg analyst Bethan Davies raised the firm's price target on Haleon to 503 GBp from 502 GBp and keeps a Buy rating on the shares.

Berenberg

NULL -> Buy

upgrade

2025-06-05

Reason

Berenberg

Price Target

2025-06-05

upgrade

NULL -> Buy

Reason

Berenberg raised the firm's price target on Haleon to 502 GBp from 460 GBp and keeps a Buy rating on the shares.

BNP Paribas Exane

Mikheil Omanadze

Neutral -> Outperform

upgrade

$13.40

2025-05-27

Reason

BNP Paribas Exane

Mikheil Omanadze

Price Target

$13.40

2025-05-27

upgrade

Neutral -> Outperform

Reason

Morgan Stanley

Equal Weight -> Overweight

upgrade

2025-05-09

Reason

Morgan Stanley

Price Target

2025-05-09

upgrade

Equal Weight -> Overweight

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Haleon PLC (HLN.N) is 0.00, compared to its 5-year average forward P/E of 15.95. For a more detailed relative valuation and DCF analysis to assess Haleon PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

15.95

Current PE

0.00

Overvalued PE

22.50

Undervalued PE

9.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

14.00

Current EV/EBITDA

14.46

Overvalued EV/EBITDA

14.94

Undervalued EV/EBITDA

13.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

2.72

Current PS

2.90

Overvalued PS

2.98

Undervalued PS

2.46